Parkinson’s plus refers to a group of neurodegenerative brain diseases that look like Parkinson’s disease at first but include additional symptoms Parkinson’s doesn’t cause. The “plus” means something extra is going on: early dementia, frequent falls, problems with eye movement, severe drops in blood pressure, or loss of coordination. These conditions progress faster than typical Parkinson’s, respond poorly to standard Parkinson’s medications, and each carries its own distinct pattern of decline.
The medical term is atypical parkinsonian syndromes. Four conditions make up the core group: progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), and dementia with Lewy bodies (DLB).
How Parkinson’s Plus Differs From Parkinson’s Disease
Parkinson’s disease and Parkinson’s plus syndromes share a foundation of similar motor symptoms: stiffness, slowness of movement, tremor, and balance problems. The critical difference is what happens beyond those basics and how quickly things change.
In typical Parkinson’s, the drug levodopa reliably improves motor symptoms, and people often maintain good function for years. In Parkinson’s plus syndromes, levodopa either doesn’t work or barely helps. In studies using a standardized motor exam, roughly 89% of people with PSP showed no meaningful improvement after levodopa, and about 77% of people with MSA had no response either. If someone with parkinsonian symptoms gets no benefit from levodopa, that’s one of the strongest signals that something other than Parkinson’s disease is at play.
Other red flags that point toward a Parkinson’s plus diagnosis include: needing a wheelchair within five years, frequent falls starting in the first three years, severe problems with blood pressure or bladder control early on, difficulty swallowing or speaking within the first five years, and symptoms that affect both sides of the body equally from the start. In Parkinson’s disease, symptoms typically begin on one side and stay noticeably worse on that side for years.
Progressive Supranuclear Palsy (PSP)
PSP is defined by its effect on eye movement. People gradually lose the ability to move their eyes vertically, particularly looking downward. This makes everyday tasks surprisingly difficult: reading, walking down stairs, even eating becomes messy because you can’t see your plate. The condition also causes early and prominent balance problems, with unexplained backward falls often appearing within the first three years.
Doctors sometimes describe a characteristic facial appearance in PSP. The forehead muscles overwork to compensate for limited eye movement, creating a wide-eyed, surprised expression. Blinking slows dramatically. Some people develop a stiff neck that pulls the head backward. Cognitive changes tend to involve slowed thinking and difficulty with planning rather than memory loss.
On brain MRI, PSP produces a recognizable pattern: the midbrain shrinks while the pons (the structure just below it) stays normal. On a side-view scan, this creates what radiologists call the “hummingbird sign,” because the shrunken midbrain resembles the head of a hummingbird perched on the body of the pons. This sign has been reported to have close to 100% sensitivity for PSP and doesn’t appear in Parkinson’s disease or the other plus syndromes.
Multiple System Atrophy (MSA)
MSA stands out for the severity of its autonomic symptoms, meaning the body’s automatic functions break down. Blood pressure drops sharply when standing, the bladder stops working properly, and in men, erectile dysfunction is so common that its absence actually argues against the diagnosis. These problems can appear before any movement symptoms do.
MSA comes in two subtypes. MSA-P (parkinsonian) primarily causes stiffness and slow movement, resembling Parkinson’s disease. MSA-C (cerebellar) primarily causes coordination problems, unsteady walking, and slurred speech. Despite these different motor profiles, the autonomic problems are equally severe in both subtypes. Inspiratory stridor, a high-pitched sound when breathing in caused by the vocal cords not opening properly, is a distinctive and dangerous feature of MSA that doesn’t occur in other parkinsonian conditions.
On MRI, MSA can produce the “hot cross bun sign,” a pattern on the pons that resembles the cross pattern on a hot cross bun, caused by selective loss of nerve cells.
Corticobasal Degeneration (CBD)
CBD is perhaps the most unusual of the group because it attacks both movement and higher brain functions in a strikingly lopsided way. One side of the body becomes much more affected than the other, with severe stiffness, difficulty making purposeful movements, and sometimes involuntary jerking.
The hallmark feature is apraxia, present at the start of illness in about 45% of people and eventually developing in roughly 57%. Apraxia means knowing what you want to do but being unable to make your body carry out the action. It typically starts in one hand and might show up as an inability to use a tool correctly or perform a familiar gesture on command, even though the muscles themselves still work.
About 30% of people with CBD experience the alien limb phenomenon, where one hand or arm seems to move on its own. This goes beyond simple involuntary twitching. The limb may reach out and grab objects, interfere with what the other hand is doing, or make complex movements that feel completely outside the person’s control. People describe the limb as having “a will of its own.”
Dementia With Lewy Bodies (DLB)
DLB blurs the line between a movement disorder and a dementia. Its core features are cognitive fluctuations, where mental clarity can shift dramatically over hours or days; vivid, detailed visual hallucinations, often of people or animals; REM sleep behavior disorder, where people physically act out their dreams; and parkinsonian motor symptoms.
What separates DLB from Parkinson’s disease with dementia is timing. In DLB, cognitive problems appear early, either before or within a year of any movement symptoms. In Parkinson’s, motor symptoms typically precede dementia by many years. People with DLB are also unusually sensitive to antipsychotic medications, which can cause severe and sometimes dangerous reactions.
Why Diagnosis Takes So Long
Getting the right diagnosis is one of the most frustrating parts of living with a Parkinson’s plus syndrome. Research comparing PSP and CBD patients with matched Parkinson’s patients found that reaching a correct, stable diagnosis took a median of about 4 years from the first symptom for PSP and CBD, compared to under 1 year for Parkinson’s disease. The initial parkinsonian symptoms can look identical, and the distinguishing “plus” features often emerge gradually.
Many people with these conditions are first diagnosed with Parkinson’s disease. Only when levodopa fails to help, when falls become frequent, or when cognitive or autonomic symptoms progress faster than expected does the diagnosis shift. Brain imaging can support the diagnosis, with specific patterns like the hummingbird sign for PSP or the hot cross bun sign for MSA, but no single test is definitive in the early stages.
Treatment and What to Expect
There are no medications that slow or stop any of the Parkinson’s plus syndromes. Treatment focuses entirely on managing symptoms and maintaining quality of life for as long as possible.
A trial of levodopa is still standard, because a small percentage of people, particularly those with MSA-P, get some temporary motor benefit. For the autonomic problems common in MSA, managing blood pressure drops involves practical steps like increasing salt and fluid intake, wearing compression garments, and rising slowly from sitting or lying positions. Medications that raise blood pressure can help in more severe cases.
Physical therapy plays a central role across all four conditions, focusing on fall prevention, maintaining mobility, and adapting to changing balance. Speech therapy becomes important as swallowing and speech difficulties develop. Occupational therapy helps people adapt daily tasks as hand coordination declines.
These conditions progress faster than Parkinson’s disease in terms of functional decline. Many people need a walking aid or wheelchair within five years. In one study, median survival from symptom onset was about 6 years for PSP and CBD, compared to about 7 years for age-matched Parkinson’s patients, though the range varied widely in both groups. The faster functional decline, rather than a dramatically shorter lifespan, is what distinguishes the day-to-day experience of living with a Parkinson’s plus syndrome.